A company delivering 67% year-over-year revenue growth with strong price momentum, rising on-balance volume, and a 4.4-to-1 favorable risk/reward offers a compelling long-term opportunity, but 3 of the 4 most recent quarters missed earnings estimates, a forward price-to-earnings of 137x demands flawless execution, and revenue concentration in two lead products creates meaningful fragility that warrants careful position sizing.
Thesis pillars
- Product Concentration Fragility↑Improving
- Hypergrowth Revenue Ramp→Stable
- Sustained Price Momentum→Stable
- +2 more pillars — see the Why tab for full reasoning
BridgeBio Pharma, Inc. (BBIO) Stock Analysis
Healthcare · Biotechnology
Sell if holding. At $84.00, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Concentration risk — Product: Attruby and Beyonttra.
BridgeBio Pharma commercializes Attruby (acoramidis) for ATTR-CM in the U.S. and develops therapies for genetic diseases. Attruby generated $362.4 million in U.S. net product revenues in 2025; Beyonttra contributed $105.0 million in license revenue via Bayer (Europe) and Alexion... Read more
Sell if holding. At $84.00, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Concentration risk — Product: Attruby and Beyonttra. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-26Recent Developments — BridgeBio Pharma, Inc.
Latest news
- NEWS BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus — GuruFocus positive
- NEWS BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha — Seeking Alpha positive
- NEWS Why BridgeBio Pharma (BBIO) Is Down 6.4% After Attruby’s Faster-Than-Expected Commercial Ramp - And What's Next - simply — simplywall.st negative
- NEWS Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail — The Globe and Mail positive
- NEWS BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus — GuruFocus positive
Generated 2026-07-26T08:02:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAttruby and Beyonttra10-K Item 1A: 'Our business is substantially dependent on the commercial success of Attruby and Beyonttra'
Material Events(8-K, last 90d)
- 2026-05-08Item 1.01LOWBridgeBio entered an Equity Distribution Agreement with Goldman Sachs and Leerink Partners on May 7, 2026 for an at-the-market offering of up to $500 million in common stock, filed alongside a Form S-3ASR registration statement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $84.00, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Concentration risk — Product: Attruby and Beyonttra. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $78.14. Score 5.3/10, moderate confidence.
Take-profit target: $94.73 (+12.7% upside). Prior stop was $78.14. Stop-loss: $78.14.
Concentration risk — Product: Attruby and Beyonttra; Consecutive earnings misses (3); Expensive valuation.
BridgeBio Pharma, Inc. trades at a P/E of N/A (forward 147.7). TrendMatrix value score: 2.6/10. Verdict: Sell.
30 analysts cover BBIO with a consensus score of 4.2/5. Average price target: $105.
What does BridgeBio Pharma, Inc. do?BridgeBio Pharma commercializes Attruby (acoramidis) for ATTR-CM in the U.S. and develops therapies for genetic...
BridgeBio Pharma commercializes Attruby (acoramidis) for ATTR-CM in the U.S. and develops therapies for genetic diseases. Attruby generated $362.4 million in U.S. net product revenues in 2025; Beyonttra contributed $105.0 million in license revenue via Bayer (Europe) and Alexion (Japan). Three Phase 3 programs—infigratinib, BBP-418, and encaleret—each reported positive data in 2025-2026 with NDA submissions planned for 2026.